EP-104IAR 25 mg
EP-104IAR-201
Phase 2 small_molecule completed
Quick answer
EP-104IAR 25 mg for Osteoarthritis, Knee is a Phase 2 program (small_molecule) at EUPRAXIA PHARMACEUTICALS INC. with 1 ClinicalTrials.gov record(s).
Program details
- Company
- EUPRAXIA PHARMACEUTICALS INC.
- Indication
- Osteoarthritis, Knee
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- completed